Evidence map›Paper›PMID 38569907›Full record

ArticleInternal medicine (Tokyo, Japan)2024

FOXA1/CK7-positive Esophageal Squamous Cell Carcinoma with Aggressive Liver Metastasis.

Hiroto Inoue, Osamu Inatomi, Hiroshi Matsumoto, Hidenori Kimura, Takahisa Nakayama, Atsushi Nishida, Akira Andoh

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hiroto InoueDivision of Digestive Endoscopy, Shiga University of Medical Science, Japan.
Osamu InatomiDivision of Gastroenterology, Department of Medicine, Shiga University of Medical Science, Japan.
Hiroshi MatsumotoDivision of Gastroenterology, Department of Medicine, Shiga University of Medical Science, Japan.
Hidenori KimuraDivision of Digestive Endoscopy, Shiga University of Medical Science, Japan.
Takahisa NakayamaDivision of Human Pathology, Shiga University of Medical Science, Japan.
Atsushi NishidaDivision of Gastroenterology, Department of Medicine, Shiga University of Medical Science, Japan.
Akira AndohDivision of Gastroenterology, Department of Medicine, Shiga University of Medical Science, Japan.
Shiga University of Medical Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytokeratin (CK) is a specific marker of adenocarcinoma. However, cases of CK7-positive esophageal squamous cell carcinoma (ESCC) have only rarely been reported. We herein report a case of unresectable CK7-positive ESCC with aggressive liver metastasis following nivolumab treatment initiation. Nivolumab treatment was discontinued after one course because of complications. Notably, the liver metastases exhibited accelerated growth. Immunostaining of the necropsy specimens revealed diffuse positivity for forkhead box protein A1 (FOXA1)/CK7, thus indicating a potent poor immune response. The potential correlation between CK7 expression and the immune checkpoint inhibitor response may offer valuable insights into the development of effective therapeutic strategies.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaHepatocyte Nuclear Factor 3-alphaKeratin-7Liver NeoplasmsBiomarkers, TumorFatal OutcomeHumansImmune Checkpoint InhibitorsNivolumabBiomarkers, TumorFOXA1 protein, humanHepatocyte Nuclear Factor 3-alphaImmune Checkpoint InhibitorsKeratin-7KRT7 protein, humanNivolumabCK7esophageal squamous cell carcinomaFOXA1immune checkpoint inhibitor

Identifiers

PMID38569907
PMCPMC11671204
OpenAlexW4393371299

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.